Dapivirine Vaginal Ring and Oral PrEP Confirmed Safe for Use During Second Trimester: Insights from the DELIVER Trial

Expanding HIV Prevention Options: The Safety and Efficacy of Dapivirine Rings in Pregnancy

Highlighting Key Findings

The MTN-042/DELIVER trial represents a significant milestone in maternal health and HIV prevention research. The study’s primary findings indicate that both the dapivirine vaginal ring (DVR) and daily oral pre-exposure prophylaxis (PrEP) are safe for use starting in the second trimester of pregnancy. No maternal deaths or HIV seroconversions occurred during the study period. Importantly, 94 percent of pregnancy outcomes were at term, and none of the observed serious adverse events were related to the use of the prevention products. These results provide essential evidence to support the inclusion of pregnant individuals in HIV prevention strategies, offering them a choice between long-acting and daily oral options.